x Neo-FBS is a lactic fermentation product of buckwheat sprouts.
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Blood-pressure-lowering Effect of Fermented Buckwheat Sprouts in Spontaneously Hypertensive Rats
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Threshold concentration 8 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1. Introduction  1 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 at a dose of 10 mg/kg BW, the positive control group was administered captopril at a dose of 10 mg/kg BW, 20 and the negative control group was administered purified water only. All administrations were performed as 21 described in section 2.5. Before the administration, the SBP and DBP of all test rats were measured by the 22 tail-cuff method. At 6 h after the administration, the SBP and DBP of test rats in each group were measured 23 again to confirm the BPL effect. Immediately after the blood pressure measurement, the rats were 24 anesthetized with diethyl ether and then exsanguinated via the abdominal aorta. Blood samples from each 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 9 20 min at 4° C to separate the plasma. The lungs, thoracic aortas, hearts, kidneys, and livers were 1 immediately excised, weighed, and then frozen. Tissue samples for ACE activity assays were prepared as 2 follows according to the previously described protocol (Horiuchi et al., 1982) . After thawing, the chopped 3 tissues were homogenized at 0° C in 50 mM Tris-HCl (pH 7.8) containing 30 mM KCl, 5 mM magnesium 4 acetate, 0.25 M sucrose, and 0.5% Nonidet P-40 in a Potter homogenizer (Iuchi, Osaka, Japan) for 5 (lungs, 5 heart, kidney, and liver) or 10 (thoracic aorta) min. The suspension was centrifuged at 12,000 g for 20 min at 6 4° C, and the supernatant was immediately used to measure ACE activity. Measurement of plasma and tissue 7 ACE activities was carried out according to the method described in the previous section. The specific 8 activity was expressed as the number of units per milligram of protein. The protein contents in the samples 9
were determined by the bicinchoninic acid assay using the BCA Protein Assay Reagent Kit (Thermo Fisher 10 Scientific K.K., Kanagawa, Japan). 11 12
SHR ring aorta assay 13
The impact of neo-FBS on vascular contractility of aortic rings in SHRs was determined by 14 constructing dose-response curves. Six individual SHRs were anesthetized with diethyl ether and then 15 sacrificed by the exsanguination described in section 2.6.2. The thoracic aorta was immediately isolated, 16 cleaned of fat and connective tissue in Krebs-Henseleit buffer solution, and cut into approximately 3-5 mm 17 rings. The ring segments were suspended on stainless steel hooks in a 5 mL organ bath containing warmed 18 (37° C) and oxygenated (O 2 :CO 2 , 19:1) Krebs-Henseleit solution. A basal tension of 1.5 g was used for the 19 tissues and changes in basal tension were recorded by an isometric force transducer (UFER UM-203; 20 (Sauvaget et al., 2010) . The presence of endothelium was confirmed by relaxation with 100 µM Ach, and 23 relaxation of at least 90% was considered evidence for the functional integrity of the endothelium. The 24 stimulant agents were removed, and the tissues were washed twice with the Krebs solution. 10 maximum contraction, the PE was washed out and the procedure was repeated once more for stabilization. 1
After the final priming step, the vascular tissues were contracted with 0.30 μM PE, and when stable 2 contraction was obtained, the neo-FBS test samples were added to the organ bath at concentrations ranging 3 from 0.50 to 100 μg/mL. The relaxation of the vascular tissue (vasorelaxation) was expressed as the 4 percentage of initial contraction baseline induced by PE. The results are expressed as the mean ± S.E. The 5 EC 50 value of the neo-FBS was calculated from the relaxation curve. At the end of each experiment, 100 µM 6 papaverine was added to the organ bath to induce complete relaxation of the aortic rings. A similar test was 7 performed using captopril in concentrations ranging from 50 to 1000 μg/mL. 8 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 The neo-FBS in this report was produced by improvements to a method that we had previously reported 23 (Nakamura et al. 2005 ). In the conventional FBS preparation, the starting material was raw juice squeezed 24 from BS that was fermented with naturally occurring lactobacillus and/or yeast in a refrigerator. The 25 fermenting mixture was frozen at about -25q C to halt the development of septic organisms. In the new 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 method, whole crushed BS was used as the starting material and the freezing step was omitted. By adding a 1 lactobacillus starter culture before fermentation, the lactate fermentation proceeded under anaerobic 2 conditions and the pH of the fermenting mixture dropped from 5.4 to 3.8 in 24 h at room temperature. The 3 low pH and anaerobic conditions suppressed the growth of E. coli and fungus at room temperature. The 4 liquid product was then squeezed from the neo-FBS when the fermentation was finished. Based on the fresh 5 weight of starting materials, the yields of liquid and lyophilized product with the new method were 68.2 and 6 1.4%, respectively, which were 7.5 and 12.7 times those from the conventional method using the same 7 starting material, BS (9.1 and 0.11%, respectively). 8 Figure 1 shows the BPL effects of neo-FBS after a single oral administration to 13-week-old male 11
SHRs at doses of 0.010 and 0.10 mg/kg BW together with positive and negative control groups. At a dose of 12 0.10 mg/kg BW, both SBP and DBP were significantly decreased compared with the negative control (p < 13 0.010) after a 3 h after administration. The BPL effects continued with time and were maintained for over 9 h 14 before returning to baseline levels at 24 h. The maximum effects were observed 9 h after the single oral 15 administration, and the means of SBP and DBP had decreased by 31.3 and 23.9 mm Hg compared to the 16 negative control group, respectively. Even at a 10 times lower dose (0.010 mg/kg), the BPL effect of the 17 neo-FBS on SHRs was significant, and the time-dependent changes to both SBP and DBP were similar to 18 those of rats that had received the higher dose. Significant decreases in SBP and DBP were seen 3 h after 19 administration, and the SBP and DBP values were 22.2 and 14.2 mm Hg, respectively, compared to a 20 negative control group at 9 h post-administration. In the captopril-administered group, only the SBP was 21 significantly decreased compared with the negative control. There were no significant differences between 22 the two neo-FBS doses when compared to each other, and the 0.10 mg/kg group showed a significant 23 reduction in BPL compared to the positive control. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 In vitro ACE inhibition by the neo-FBS was determined by the HPLC method (Horiuchi et al., 1982) . 1 The inhibitory activity of the neo-FBS was expressed as the IC 50 value (the concentration of neo-FBS 2 required to inhibit 50% of the ACE activity). An IC 50 value of 0.22 ± 0.01 mg/mL for the neo-FBS was 3 similar to the value 0.24 ± 0.03 mg/mL obtained for material prepared by the conventional method. The IC 50 4 value of captopril was 20 ± 1.2 ng/mL in our assay. 5
The in vivo ACE activities of body tissues (plasma, lungs, thoracic aorta, heart, kidney, and liver) from 6 test groups at 6 h after administration were also determined in a similar manner. As shown in Fig. 2 , at the 10 7 mg/kg dose of neo-FBS, the mean values of ACE activities of plasma, lungs, thoracic aorta, heart, kidney, 8 and liver were 82.5 mU/mL, and 54.9, 19.2, 0.15, 0.72, and 0.021 mU/mg of protein, respectively. On the 9 other hand, those of the negative control group administered purified water only were 78.1 mU/mL and 70.2 ,1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 Figure 3 shows a typical relaxation profile upon addition of neo-FBS to endothelium-intact thoracic 2 aorta rings that had been pre-contracted with 0.30 μM PE. The neo-FBS had a dose-dependent 3 vasorelaxation effect on the blood vessel rings. Figure 4 shows a relaxation curve made by plotting the mean 4 values of six individual tests of endothelium-intact thoracic aorta rings. The threshold concentration (TC) for 5 the neo-FBS to induce significant vasorelaxation was only 0.50 μg/mL, and 50 μg/mL produced a maximum 6 relaxation effect of 82.8 ± 3.7%. The effective concentration causing 50% relaxation (EC 50 ) of 7 PE-precontracted thoracic aorta was calculated as 8.3 ± 1.4 μg/mL. When 100 µM papaverine was added to 8 the organ bath at the end of the experiment, 3.2 ± 1.8% relaxation of the aorta rings was observed. On the 9 other hand, the percentage of vasorelaxation caused by captopril was only 12.0 ± 5.3% even at 10 concentrations as high as 1000 μg/mL. 11 12
Vasorelaxing effect of the neo-FBS 1

Content of phenols in BS and neo-FBS 13
To confirm participation of phenols present in BS in the BPL action of neo-FBS, we determined the 14 contents of these compounds in BS and neo-FBS. Table 1 shows the quantities of total phenols and five kinds 15 of major flavonoids in BS and neo-FBS. Total phenols in BS and neo-FBS were determined by the 16 Folin-Ciocalteau method and the results were expressed as gallic acid equivalents. The amounts of total 17 phenols were 40.5 ± 0.3 and 43.0 ± 1.2 mg/g DW gallic acid equivalents, respectively. The contents of 18 orientin, isoorientin, vitexin, isovitexin, and rutin were determined by the method previously reported 19 (Koyama et al., 2010) and were expressed as rutin equivalents. The results showed that the contents of 20 isoorientin and rutin were significantly decreased in neo-FBS, but the contents of the other flavonoids 21 remained the same. As a result, the total phenol content was the same in both preparations, but the amounts 22 of rutin and isoorientin in neo-FBS were lower than those in BS. 23 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 15 fermented buckwheat sprouts that we have termed neo-FBS. The BPL effect of the raw BS was much weaker 1 than that of the neo-FBS, and the starter culture of Lactobacillus plantarum did not have any BPL effect 2 (data not shown). The neo-FBS production process was basically the same as the traditional production 3 method of unsalted, pickled vegetables except for the fermentation temperature (Watanabe et al., 2009 ). The 4 neo-FBS was produced at room temperature, while traditional Japanese pickled vegetables are manufactured 5 at low temperatures to suppress the growth of septic organisms. By adding a starter culture of Lactobacillus 6 to easily consumed, crushed BS, the lactic acid fermentation process started quickly and lowered the pH fast1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 distinguished by its ability to inhibit ACE activity in the thoracic aorta and heart to a greater extent than 1
captopril. 2
The in vitro ACE inhibitory activity of captopril (IC 50 , 20 ng/mL) was much stronger than that of the 3 neo-FBS (0.22 mg/mL). However, our results suggest that the in vivo ACE inhibitory activity of neo-FBS is 4 not significantly different from that of captopril at the same dose. Furthermore, as described in section 3.2, 5 the BPL effect of neo-FBS in SHRs was superior to that of captopril because neo-FBS demonstrated the 6 same BPL effect as captopril but at a thousand times lower dose. Thus, the in vivo data does not correlate 7 with the in vitro data for ACE inhibition. It has been reported that other food-derived ACE inhibitory 8 peptides possess higher BPL effects than would be expected from their in vitro ACE inhibitory activities 9 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
1996). 3
Several studies have reported that phenolic compounds contained in plant body have bioactivities 4 (Chandrasekara & Shahidi, 2011; Cheng et al., 2009; Li et al., 2009) . Therefore, these potent BPL actions of 5 neo-FBS are expected to be caused by an increase in the amount of BPL compounds, including phenols, in 6 BS during the lactic fermentation. Rutin, orientin, and isoorientin are BPL compounds in buckwheat that 7 have been described before (Fu et al., 2005; Fusi et al., 2003) . Quantitative analysis of the buckwheat 8 phenols in BS and neo-FBS showed that rutin and isoorientin were significantly decreased in neo-FBS but 9
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